Evaluation of potentially inappropriate medication in older patients with cardiovascular diseases—STOPP/START-based study

Objective This study aims to evaluate the use of STOPP/START criteria in the identification of Potentially inappropriate medication and potential prescribing omissions in older patients with cardiovascular diseases in Bulgaria. Excessive morbidity and mortality has been linked to drug-related problems and increased use of healthcare services and is an understudied problem for Bulgaria. Materials and methods A prospective, questionnaire-based study was conducted among 543 older patients across 25 pharmacies in Bulgaria. Socio-demographic characteristic, disease profile, symptoms, and medication data were collected. The questionnaire was developed for the purposes of the EUROAGEISM project. Out of all 543 patients, only those with documented cardio-vascular diseases were extracted and the medication profile per patient was evaluated for Potentially inappropriate medication (PIMs) and potentially prescribing omissions (PPOs) using STOPP/START criteria version 2. In addition, several risks for potentially inappropriate prescribing (PIPs), PPOs and PIMs were calculated with the focus being on the Odds and Risks to develop a PIP. Results Four hundred and twenty eight from 531 patients with known therapy for cardiovascular diseases (CVDs) were included in the analysis of PIP (40.52% aged 65–69 years, 61.88% female, 64% had up to 6 comorbidities, and 21.72% presenting with polypharmacy). A total of 71 PIMs in 64 patients with polypharmacy were identified during applying STOPP criteria. 56% of patients taking above five medicines daily had PIMs. The majority of PIMs (31%) were related to CVDs treatment, followed by PIMs in the treatment of endocrine diseases (22.54%), duplication of medicines (8.46%) and prolonged treatment with benzodiazepines (8.46%). Forty four PPOs were identified with START criteria. 22.72% were related to lack of proton pump inhibitors (PPI) in the presence of gastroesophageal disorders, and the same percentage was for lack of Calcium-vitamin D supplementation in osteoporosis. Applying the methodology of risks calculation the sample risk for PPO was 2.1% and for PIM 3.4%. At sample level the relative risk for PPO was 62% out of the risk for PIM and at population level varied between 42.8 and 89.8% and it is statistically significant. The number needed to treat for the event to happen is 77.5, meaning that at every 78 prescriptions there is a chance to appear PIP. Conclusion Application of methodologies for detection of potentially inappropriate prescribing is not part of routine clinical practice in Bulgaria. Our study demonstrates a high percentage of potentially inappropriate medication among older patients with polypharmacy. Along with the aging population in Bulgaria, economic burden of polypharmacy and the prevalence of cardiovascular diseases, it is especially important to address potentially inappropriate medication use in cardiovascular patients. There is a considerable necessity for implementation of measures for early detection of potentially inappropriate medication and potentially prescribing omission as a part of de-prescribing strategies in older patients.

[1]  K. Tachkov,et al.  Impact of Polypharmacy, Drug-Related Problems, and Potentially Inappropriate Medications in Geriatric Patients and Its Implications for Bulgaria—Narrative Review and Meta-Analysis , 2022, Frontiers in Public Health.

[2]  M. Baré,et al.  Factors associated to potentially inappropriate prescribing in older patients according to STOPP/START criteria: MoPIM multicentre cohort study , 2022, BMC Geriatrics.

[3]  E. Manias,et al.  Potentially inappropriate prescribing and its associations with health‐related and system‐related outcomes in hospitalised older adults: A systematic review and meta‐analysis , 2021, British journal of clinical pharmacology.

[4]  K. Taxis,et al.  Trends in polypharmacy and potentially inappropriate medication (PIM) in older and middle‐aged people treated for diabetes , 2020, British journal of clinical pharmacology.

[5]  A. Pariente,et al.  The Burden of Potentially Inappropriate Medications in Chronic Polypharmacy , 2020, Journal of clinical medicine.

[6]  Henrique Souza Barros de Oliveira,et al.  Risk factors associated with potential cardiovascular and cerebrovascular adverse events in elderly individuals assisted at secondary level. , 2020, Revista da Associacao Medica Brasileira.

[7]  J. Haro,et al.  Multimorbidity patterns in low-middle and high income regions: a multiregion latent class analysis using ATHLOS harmonised cohorts , 2020, BMJ Open.

[8]  J. Machado-Alba,et al.  Potential prescribing omissions in patients with cardiovascular disease , 2019, International journal of clinical practice.

[9]  D. O’Mahony STOPP/START criteria for potentially inappropriate medications/potential prescribing omissions in older people: origin and progress , 2019, Expert review of clinical pharmacology.

[10]  S. Dobrić,et al.  Potentially Inappropriate Prescribing and Potential Clinically Significant Drug–Drug Interactions in Older Outpatients: Is There Any Association? , 2019, Medicina.

[11]  P. Doró,et al.  Applicability of EU(7)-PIM criteria in cross-national studies in European countries , 2019, Therapeutic advances in drug safety.

[12]  S. Panguluri,et al.  Cardiovascular Risks Associated with Gender and Aging , 2019, Journal of cardiovascular development and disease.

[13]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[14]  A. Abu-Hanna,et al.  Potentially inappropriate prescribing to older patients in primary care in the Netherlands: a retrospective longitudinal study , 2017, Age and ageing.

[15]  A. Majeed,et al.  Current and future perspectives on the management of polypharmacy , 2017, BMC Family Practice.

[16]  C. Hughes,et al.  Evaluating the prevalence of potentially inappropriate prescribing in older adults in intermediate care facilities: a cross-sectional observational study , 2017, International Journal of Clinical Pharmacy.

[17]  V. Briedis,et al.  The use of potentially inappropriate medications among the Lithuanian elderly according to Beers and EU(7)‐PIM list – a nationwide cross‐sectional study on reimbursement claims data , 2017, Journal of clinical pharmacy and therapeutics.

[18]  Jocelyn R. Wilder,et al.  Changes in Prescription and Over-the-Counter Medication and Dietary Supplement Use Among Older Adults in the United States, 2005 vs 2011. , 2016, JAMA internal medicine.

[19]  M. Steinman Polypharmacy-Time to Get Beyond Numbers. , 2016, JAMA internal medicine.

[20]  P. Johnson,et al.  Nondisclosure of Complementary and Alternative Medicine Use to Primary Care Physicians: Findings From the 2012 National Health Interview Survey. , 2016, JAMA internal medicine.

[21]  Paul Gallagher,et al.  Predicting risk of adverse drug reactions in older adults , 2016, Therapeutic advances in drug safety.

[22]  Mary Jordan Samuel American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults , 2015, Journal of the American Geriatrics Society.

[23]  G. Meyer,et al.  The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries , 2015, European Journal of Clinical Pharmacology.

[24]  Paul Gallagher,et al.  STOPP/START criteria for potentially inappropriate prescribing in older people: version 2 , 2014, Age and ageing.

[25]  Tanisha Jowsey,et al.  Multimorbidity and Comorbidity of Chronic Diseases among the Senior Australians: Prevalence and Patterns , 2014, PloS one.

[26]  K. Ueng,et al.  The impact of number of drugs prescribed on the risk of potentially inappropriate medication among outpatient older adults with chronic diseases. , 2013, QJM : monthly journal of the Association of Physicians.

[27]  J. Peris,et al.  Potentially inappropriate prescribing in institutionalised older patients in Spain: the STOPP-START criteria compared with the Beers criteria , 2012, Pharmacy practice.

[28]  J. Baeyens,et al.  Prevalence of potentially inappropriate prescribing in an acutely ill population of older patients admitted to six European hospitals , 2011, European Journal of Clinical Pharmacology.

[29]  Nick Barber,et al.  Appropriate prescribing in elderly people: how well can it be measured and optimised? , 2007, The Lancet.

[30]  M. Cesari,et al.  Anticholinergic Drugs and Physical Function Among Frail Elderly Population , 2007, Clinical pharmacology and therapeutics.

[31]  K. Hersberger,et al.  Drug-Related Problem Classification Systems , 2004, The Annals of pharmacotherapy.

[32]  B. Starfield,et al.  Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. , 2002, Archives of internal medicine.

[33]  M. Afilalo,et al.  Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. , 2001, Annals of emergency medicine.

[34]  D. Sackett,et al.  Evidence based medicine: what it is and what it isn't , 1996, BMJ.

[35]  G. Stojanović,et al.  Potentially inappropriate medications prescribing among elderly patients with cardiovascular diseases , 2020 .

[36]  P. Church - What it IS and ISN'T - , 2015 .

[37]  G. Onder,et al.  Explicit Criteria for Potentially Inappropriate Medications to Reduce the Risk of Adverse Drug Reactions in Elderly People , 2012, Drug Safety.

[38]  B. Norrving,et al.  Global atlas on cardiovascular disease prevention and control. , 2011 .

[39]  K. Shadan,et al.  Available Online at , 2002 .

[40]  Marjan van den Akker,et al.  Open Access Research Article Prevalence Estimates of Multimorbidity: a Comparative Study of Two Sources , 2022 .